carvedilol has been researched along with Pulmonary Hypertension in 11 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| " • Carvedilol reduced biventricular TGFβ1-CTGF signaling, fibrosis, and apoptosis." | 7.81 | Carvedilol improves biventricular fibrosis and function in experimental pulmonary hypertension. ( Breitling, S; Friedberg, MK; Honjo, O; Kato, H; Kuebler, WM; Okumura, K; Sun, M, 2015) |
| "We report a case of macroscopic T-wave alternans occurring 30 min before the onset of amiodarone-induced torsade de pointes, illustrating a means to monitor for proarrhythmia." | 7.78 | In-hospital monitoring of T-wave alternans in a case of amiodarone-induced torsade de pointes: clinical and methodologic insights. ( Aoyama, T; Hattori, A; Kanamori, H; Kawaguchi, T; Kawasaki, M; Kubota, T; Minatoguchi, S; Nishigaki, K; Takasugi, M; Takasugi, N; Takemura, G; Ushikoshi, H; Verrier, RL, 2012) |
| "To study the condition of the sympathico-adrenal system (SAS), synthesis of cAMP dependent on beta2-adrenoreceptors and parameters of free radical oxidation in patients with primary pulmonary hypertension (PPH); to examine efficacy of non-selective beta- and alpha1-adrenoblocker carvedilol in PPH patients." | 7.73 | [Primary pulmonary hypertension: activation of sympathico-adrenal system and free radical oxidation. Positive effects of carvedilol therapy]. ( Aref'eva, TI; Ataullakhanova, DM; Chazova, IE; Irodova, NL; Konovalova, GG; Krasnikova, TL; Lankin, VZ; Lazutkina, VK; Masenko, VP; Orlova, IaA; Sokolov, SF, 2005) |
| "To evaluate carvedilol effect on clinical state, norepinephrine (NE) and epinephrine (E) plasma concentration and lymphocyte beta 2-adrenoreceptor dependent cAMP synthesis in patients with primary pulmonary hypertension (PPH)." | 7.71 | [Carvedilol in treating primary pulmonary hypertension patients: effect on severity of cardiac failure, degree of pulmonary hypertension, concentration of catecholamines in blood plasma and dependence of cyclic AMP synthesis in lymphocytes on beta-adrener ( Chazova, IE; Irodova, NL; Kochetov, AG; Krasnikova, TL; Masenko, VP, 2002) |
| "Genes encoding proteins in the cardiac hypertrophy and protein ubiquitination pathways were downregulated in the RV by carvedilol, while genes encoding proteins in the mitochondrial dysfunction pathway were upregulated by carvedilol." | 5.39 | Chronic carvedilol treatment partially reverses the right ventricular failure transcriptional profile in experimental pulmonary hypertension. ( Bogaard, HJ; Drake, JI; Dumur, CI; Fawcett, P; Gomez-Arroyo, J; Kraskauskas, D; Natarajan, R; Voelkel, NF, 2013) |
| " • Carvedilol reduced biventricular TGFβ1-CTGF signaling, fibrosis, and apoptosis." | 3.81 | Carvedilol improves biventricular fibrosis and function in experimental pulmonary hypertension. ( Breitling, S; Friedberg, MK; Honjo, O; Kato, H; Kuebler, WM; Okumura, K; Sun, M, 2015) |
| "We report a case of macroscopic T-wave alternans occurring 30 min before the onset of amiodarone-induced torsade de pointes, illustrating a means to monitor for proarrhythmia." | 3.78 | In-hospital monitoring of T-wave alternans in a case of amiodarone-induced torsade de pointes: clinical and methodologic insights. ( Aoyama, T; Hattori, A; Kanamori, H; Kawaguchi, T; Kawasaki, M; Kubota, T; Minatoguchi, S; Nishigaki, K; Takasugi, M; Takasugi, N; Takemura, G; Ushikoshi, H; Verrier, RL, 2012) |
| "To assess the effect of the adrenergic receptor blocker carvedilol on the pulmonary circulation and right heart in experimental pulmonary hypertension in rats." | 3.76 | Adrenergic receptor blockade reverses right heart remodeling and dysfunction in pulmonary hypertensive rats. ( Abbate, A; Bogaard, HJ; Chang, PJ; Chau, VQ; Hoke, NN; Kasper, M; Kraskauskas, D; Mizuno, S; Natarajan, R; Salloum, FN; Voelkel, NF, 2010) |
| "To study the condition of the sympathico-adrenal system (SAS), synthesis of cAMP dependent on beta2-adrenoreceptors and parameters of free radical oxidation in patients with primary pulmonary hypertension (PPH); to examine efficacy of non-selective beta- and alpha1-adrenoblocker carvedilol in PPH patients." | 3.73 | [Primary pulmonary hypertension: activation of sympathico-adrenal system and free radical oxidation. Positive effects of carvedilol therapy]. ( Aref'eva, TI; Ataullakhanova, DM; Chazova, IE; Irodova, NL; Konovalova, GG; Krasnikova, TL; Lankin, VZ; Lazutkina, VK; Masenko, VP; Orlova, IaA; Sokolov, SF, 2005) |
| "To evaluate carvedilol effect on clinical state, norepinephrine (NE) and epinephrine (E) plasma concentration and lymphocyte beta 2-adrenoreceptor dependent cAMP synthesis in patients with primary pulmonary hypertension (PPH)." | 3.71 | [Carvedilol in treating primary pulmonary hypertension patients: effect on severity of cardiac failure, degree of pulmonary hypertension, concentration of catecholamines in blood plasma and dependence of cyclic AMP synthesis in lymphocytes on beta-adrener ( Chazova, IE; Irodova, NL; Kochetov, AG; Krasnikova, TL; Masenko, VP, 2002) |
| "Genes encoding proteins in the cardiac hypertrophy and protein ubiquitination pathways were downregulated in the RV by carvedilol, while genes encoding proteins in the mitochondrial dysfunction pathway were upregulated by carvedilol." | 1.39 | Chronic carvedilol treatment partially reverses the right ventricular failure transcriptional profile in experimental pulmonary hypertension. ( Bogaard, HJ; Drake, JI; Dumur, CI; Fawcett, P; Gomez-Arroyo, J; Kraskauskas, D; Natarajan, R; Voelkel, NF, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (45.45) | 29.6817 |
| 2010's | 6 (54.55) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gomez, O | 1 |
| Okumura, K | 2 |
| Honjo, O | 2 |
| Sun, M | 2 |
| Ishii, R | 1 |
| Bijnens, B | 1 |
| Friedberg, MK | 2 |
| Drake, JI | 1 |
| Gomez-Arroyo, J | 1 |
| Dumur, CI | 1 |
| Kraskauskas, D | 2 |
| Natarajan, R | 2 |
| Bogaard, HJ | 3 |
| Fawcett, P | 1 |
| Voelkel, NF | 3 |
| Grinnan, D | 1 |
| Grizzard, J | 1 |
| Van Tassell, B | 1 |
| Abbate, A | 2 |
| DeWilde, C | 1 |
| Priday, A | 1 |
| Kato, H | 1 |
| Breitling, S | 1 |
| Kuebler, WM | 1 |
| Mizuno, S | 1 |
| Chang, PJ | 1 |
| Chau, VQ | 1 |
| Hoke, NN | 1 |
| Kasper, M | 1 |
| Salloum, FN | 1 |
| Kawaguchi, T | 1 |
| Takasugi, N | 1 |
| Kubota, T | 1 |
| Takasugi, M | 1 |
| Kanamori, H | 1 |
| Ushikoshi, H | 1 |
| Hattori, A | 1 |
| Aoyama, T | 1 |
| Kawasaki, M | 1 |
| Nishigaki, K | 1 |
| Takemura, G | 1 |
| Minatoguchi, S | 1 |
| Verrier, RL | 1 |
| Irodova, NL | 2 |
| Krasnikova, TL | 2 |
| Masenko, VP | 2 |
| Kochetov, AG | 1 |
| Chazova, IE | 2 |
| Aref'eva, TI | 1 |
| Lazutkina, VK | 1 |
| Orlova, IaA | 1 |
| Sokolov, SF | 1 |
| Ataullakhanova, DM | 1 |
| Konovalova, GG | 1 |
| Lankin, VZ | 1 |
| Fujio, H | 1 |
| Nakamura, K | 1 |
| Matsubara, H | 1 |
| Kusano, KF | 1 |
| Miyaji, K | 1 |
| Nagase, S | 1 |
| Ikeda, T | 1 |
| Ogawa, A | 1 |
| Ohta-Ogo, K | 1 |
| Miura, D | 1 |
| Miura, A | 1 |
| Miyazaki, M | 1 |
| Date, H | 1 |
| Ohe, T | 1 |
| Valencia Ortega, ME | 1 |
| Ortega Millán, G | 1 |
| Guinea Esquerdo, J | 1 |
| Laguna Cuesta, F | 1 |
| Moreno Celda, V | 1 |
| Gónzalez Lahoz, J | 1 |
| Eulalia Valencia, M | 1 |
| Guinea, J | 1 |
| Moreno, V | 1 |
| González-Lahoz, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Pilot Study of the Safety and Efficacy of Carvedilol in Pulmonary Arterial Hypertension[NCT00964678] | Phase 1/Phase 2 | 10 participants (Actual) | Interventional | 2010-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Change in right ventricular ejection fraction is measured by cardiac magnetic resonance imaging, using the method of disks with the reading radiologist being blinded to before and after images. Cardiac magnetic resonance imaging was done at baseline and 6 months only (NCT00964678)
Timeframe: baseline, 6 months
| Intervention | % RVEF (Mean) |
|---|---|
| Carvedilol | 10.4 |
(NCT00964678)
Timeframe: baseline and 6 months
| Intervention | feet (Number) | ||||
|---|---|---|---|---|---|
| Participant 1 | Participant 2 | Participant 3 | Participant 5 | Participant 6 | |
| Carvedilol | 45 | 160 | 35 | 5 | 96 |
right ventricular end systolic volume determined by MRI (NCT00964678)
Timeframe: baseline and 6 months
| Intervention | mL (Number) | |||||
|---|---|---|---|---|---|---|
| Participant 1 | Participant 2 | Participant 3 | Participant 4 | Participant 5 | Participant 6 | |
| Carvedilol | 3 | 14 | 56 | 11 | 27 | 25 |
Higher values indicate a better outcome. (NCT00964678)
Timeframe: baseline and 6 months
| Intervention | centimeters (Number) | ||||
|---|---|---|---|---|---|
| Participant 1 | Participant 2 | Participant 4 | Participant 5 | Participant 6 | |
| Carvedilol | 0.4 | -0.08 | -0.12 | 0.45 | 0.08 |
1 trial available for carvedilol and Pulmonary Hypertension
| Article | Year |
|---|---|
Treatment of group I pulmonary arterial hypertension with carvedilol is safe.
Topics: Adrenergic beta-Antagonists; Aged; Carbazoles; Carvedilol; Drug Administration Schedule; Familial Pr | 2014 |
10 other studies available for carvedilol and Pulmonary Hypertension
| Article | Year |
|---|---|
Heart rate reduction improves biventricular function and interactions in experimental pulmonary hypertension.
Topics: Adrenergic beta-Antagonists; Animals; Anti-Arrhythmia Agents; Carvedilol; Disease Models, Animal; Dr | 2018 |
Chronic carvedilol treatment partially reverses the right ventricular failure transcriptional profile in experimental pulmonary hypertension.
Topics: Animals; Carbazoles; Cardiomegaly; Carvedilol; Cluster Analysis; Gene Expression Profiling; Gene Exp | 2013 |
Carvedilol improves biventricular fibrosis and function in experimental pulmonary hypertension.
Topics: Animals; Antihypertensive Agents; Carbazoles; Carvedilol; Connective Tissue Growth Factor; Fibrosis; | 2015 |
Adrenergic receptor blockade reverses right heart remodeling and dysfunction in pulmonary hypertensive rats.
Topics: Adrenergic Antagonists; Animals; Carbazoles; Carvedilol; Disease Models, Animal; Hypertension, Pulmo | 2010 |
In-hospital monitoring of T-wave alternans in a case of amiodarone-induced torsade de pointes: clinical and methodologic insights.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Bundle-Branch Block; Carbazoles; Carv | 2012 |
[Carvedilol in treating primary pulmonary hypertension patients: effect on severity of cardiac failure, degree of pulmonary hypertension, concentration of catecholamines in blood plasma and dependence of cyclic AMP synthesis in lymphocytes on beta-adrener
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Carbazoles; Cardiac Output, Low; Carvedilol; Catecho | 2002 |
[Primary pulmonary hypertension: activation of sympathico-adrenal system and free radical oxidation. Positive effects of carvedilol therapy].
Topics: Adrenergic Agents; Adult; Aged; Antihypertensive Agents; Carbazoles; Carvedilol; Catalase; Female; F | 2005 |
Carvedilol inhibits proliferation of cultured pulmonary artery smooth muscle cells of patients with idiopathic pulmonary arterial hypertension.
Topics: Adolescent; Adrenergic alpha-Antagonists; Adult; Aged; Carbazoles; Carvedilol; Cell Division; Cell P | 2006 |
[Pulmonary hypertension in patients with human immunodeficiency virus infection. Study of 14 cases].
Topics: Adult; Antihypertensive Agents; Carbazoles; Carvedilol; Echocardiography, Doppler; Female; Follow-Up | 2000 |
[Severe pulmonary hypertensión treated with low dose carvedilol in a patient infected with the human immunodeficiency virus].
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Carbazoles; Carvedilol; Female; HIV Infections | 2001 |